Asset profile

Pembrolizumab

Monoclonal antibody

ApprovedPD-1
Approvedregulatory verdict

Evidence outlook

Approved — Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3

How the evidence outlook works ↗

Upcoming events

(195 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (28)
August 2026 (1)
Phase 3Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7 …Active not recruiting
Est. primary completion 2026-08-31 · NCT02954874 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (8)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-09 · NCT05887492 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-09 · NCT05186974 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2026-09-02 · NCT04340882 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-09-10 · NCT06538012 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-09-22 · NCT04370587 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-09-30 · NCT05284539 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-09-30 · NCT05609578 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma …Recruiting
Est. primary completion 2026-09-30 · NCT07407920 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (3)
Phase 1/2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2026-10 · NCT05318469 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-10-23 · NCT06008093 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast CancerNot yet recruiting
Est. primary completion 2026-10-30 · NCT07054242 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (3)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT06448312 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2ALK Gene Mutation, Lung Adenocarcinoma, ImmunotherapyRecruiting
Est. primary completion 2026-11-16 · NCT05266846 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive …Active not recruiting
Est. primary completion 2026-11-25 · NCT02955290 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (13)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06246110 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast Cancer, Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05645380 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Squamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant Melanoma, Advanced Solid TumorsActive not recruiting
Est. primary completion 2026-12 · NCT02644369 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06754644 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC - Triple-Negative Breast Cancer, Breast CancerRecruiting
Est. primary completion 2026-12-01 · NCT05491226 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-15 · NCT05669430 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-22 · NCT03774732 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Advanced Solid Tumor, Triple Negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05491083 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05675579 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT03804944 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05286437 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07162883 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (55)
January 2027 (4)
Phase 2Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT04683679 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-12 · NCT05609968 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma …Recruiting
Est. primary completion 2027-01-31 · NCT04267848 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (5)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT06228326 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple Negative Breast Cancer, PD-L1 PositiveActive not recruiting
Est. primary completion 2027-02 · NCT05382286 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2027-02-12 · NCT06492759 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (2)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-03 · NCT06400160 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Colorectal Cancer; Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT04701476 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (7)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04 · NCT04956640 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-04-01 · NCT06407310 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Triple Negative Breast Cancer, PD-L1 NegativeRecruiting
Est. primary completion 2027-04-01 · NCT04468061 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-08 · NCT04317534 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-27 · NCT06364917 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT02414269 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT05589818 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-05 · NCT04380636 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-31 · NCT05085028 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (8)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06162221 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT03546686 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2027-06 · NCT06353997 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06726265 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple Negative Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05633654 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-01 · NCT05317858 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06942234 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-06-30 · NCT05096663 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (6)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT05579366 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive, Breast Cancer Triple NegativeRecruiting
Est. primary completion 2027-07 · NCT07188246 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2027-07-01 · NCT05570825 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-14 · NCT06205706 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-30 · NCT06635824 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (6)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08 · NCT05081609 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08 · NCT05020860 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Metastatic Triple-Negative Breast CancerActive not recruiting
Est. primary completion 2027-08 · NCT06027268 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08-01 · NCT05894889 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lung Cancer, Non-squamous, Non-small CellRecruiting
Est. primary completion 2027-08-12 · NCT07486817 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT06951399 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Stage 1 cT1b-T1cN0M0, Triple Negative Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT06318897 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8Active not recruiting
Est. primary completion 2027-09-30 · NCT03793179 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10 · NCT07207395 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2027-10-20 · NCT06845319 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (5)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06772623 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast CancerRecruiting
Est. primary completion 2027-11 · NCT07276880 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06119581 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06667167 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT06142617 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT03556228 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07264816 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-12-31 · NCT03225664 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (41)
January 2028 (3)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-10 · NCT06311721 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (4)
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-02-16 · NCT07415031 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02-28 · NCT07287917 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Brain Metastases, TumorRecruiting
Est. primary completion 2028-02-28 · NCT05064280 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02-28 · NCT06472583 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03 · NCT06579196 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-23 · NCT03412877 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03-30 · NCT06644768 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2028-03-31 · NCT05269381 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)
Phase 2/3Progressive Multifocal LeukoencephalopathyNot yet recruiting
Est. primary completion 2028-04 · NCT06276504 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05 · NCT03526835 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma …Recruiting
Est. primary completion 2028-05-15 · NCT04348747 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (6)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07360743 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-11 · NCT06902272 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT04977453 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma …Recruiting
Est. primary completion 2028-06-30 · NCT05741164 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer, BRCA1 Mutation, BRCA2 Mutation …Recruiting
Est. primary completion 2028-06-30 · NCT05485766 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06822543 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-07 · NCT06882174 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (3)
Phase 2Triple Negative Breast NeoplasmsRecruiting
Est. primary completion 2028-08 · NCT05973864 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-07 · NCT06405230 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-08-15 · NCT07420439 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (3)
Phase 2Metastatic Squamous Non-Small Cell Lung CarcinomaRecruiting
Est. primary completion 2028-09 · NCT05613413 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT07016399 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09-05 · NCT06758401 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (5)
Phase 2Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast CancerRecruiting
Est. primary completion 2028-10 · NCT04230109 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10 · NCT06216301 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-13 · NCT07223047 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-31 · NCT04613596 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-31 · NCT07251582 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT06793215 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (8)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2028-12-01 · NCT07017829 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-21 · NCT07410676 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-27 · NCT01174121 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lung CancerActive not recruiting
Est. primary completion 2028-12-30 · NCT06055465 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT06492421 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT03449238 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07622186 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (26)
January 2029 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01 · NCT05098132 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-01 · NCT06045767 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2Not yet recruiting
Est. primary completion 2029-01-15 · NCT07610525 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-19 · NCT06345729 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2029 (2)
Phase 2Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating LymphocytesNot yet recruiting
Est. primary completion 2029-03-01 · NCT07743190 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-03-31 · NCT07098988 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2029 (2)
Phase 2/3Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck CancerRecruiting
Est. primary completion 2029-04 · NCT04534205 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8Recruiting
Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-05 · NCT05318573 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05 · NCT06890598 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-05-11 · NCT05555732 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06 · NCT07452224 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06245889 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Locally Advanced or Metastatic Malignant Solid TumorsRecruiting
Est. primary completion 2029-06-30 · NCT07287995 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-02 · NCT07221474 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2029 (3)
Phase 2Recurrent Triple-Negative Breast CancerRecruiting
Est. primary completion 2029-09 · NCT06976944 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple Negative Breast CancerRecruiting
Est. primary completion 2029-09 · NCT06081244 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-07 · NCT06875310 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2029 (2)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-10 · NCT07777822 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10-30 · NCT05187338 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (4)
Phase 2Triple Negative Breast Cancer, Uterine Cervical Cancer, Uterine Corpus Cancer, Malignant Melanoma, Clear Cell Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2029-12 · NCT06976021 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07756645 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Intrahepatic Cholangiocarcinoma (Icc)Recruiting
Est. primary completion 2029-12-31 · NCT07632235 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (14)
January 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT06745882 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2030 (1)
Phase 1/2Locally Advanced or Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2030-02-28 · NCT07730021 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2030 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-03-04 · NCT05215340 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-24 · NCT06899126 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2030 (1)
Phase 3Triple Negative Breast NeoplasmsRecruiting
Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2030 (3)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-06-21 · NCT07639242 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-25 · NCT07603856 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-25 · NCT06077760 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2030 (2)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2030-07-17 · NCT07751042 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-07-31 · NCT07739966 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)
Phase 1/2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2030-09 · NCT07762703 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-30 · NCT07223424 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple-Negative Breast CancerRecruiting
Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (8)
January 2031 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2031-01-24 · NCT03725059 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2031 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2031 (1)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2031-03-31 · NCT07749586 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2031 (1)
Phase 1/2Triple Negative Breast Cancer, Residual DiseaseRecruiting
Est. primary completion 2031-06-26 · NCT06134375 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2031 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-07-01 · NCT04990921 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2031 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-08-12 · NCT07063745 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2031 (2)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-10 · NCT06236438 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-10-22 · NCT07660094 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (7)
January 2032 (2)
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2032-01-01 · NCT06078384 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-01-29 · NCT05789082 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2032 (2)
Phase 2Lung Neoplasm MalignantRecruiting
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-02-13 · NCT04165070 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2032 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-03-12 · NCT06731907 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2032 (2)
Phase 3Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer …Not yet recruiting
Est. primary completion 2032-04 · NCT07486687 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-04-30 · NCT04114136 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (9)
January 2033 (2)
Phase 3Breast Cancers, Triple Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2033-01-01 · NCT06606730 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2033-01-14 · NCT07252739 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2033 (3)
Phase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast NeoplasmsRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Breast Cancer, Triple-negative Breast CancerNot yet recruiting
Est. primary completion 2033-03-31 · NCT07178730 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2033-03-31 · NCT05929768 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2033 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-05-16 · NCT06623422 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2033 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC - Triple-Negative Breast Cancer, Breast CancerNot yet recruiting
Est. primary completion 2033-07 · NCT07015853 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2033 (1)
Phase 2/3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2033-11-01 · NCT03755739 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2034 (2)
February 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-08-22 · NCT07513376 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (3)
January 2035 (1)
Phase 3Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8Recruiting
Est. primary completion 2035-01-31 · NCT06096844 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2035 (1)
Phase 3Breast Cancer, Triple Negative Breast NeoplasmsActive not recruiting
Est. primary completion 2035-09 · NCT04335669 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2035 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2035-12-31 · NCT07365319 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2036 (1)
December 2036 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2036-12-31 · NCT05669846 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2040 (1)
February 2040 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.

Educational data tool. Grades describe evidence quality, not investment merit.